Avalo Therapeutics (AVTX) Leases (2019 - 2025)
Historic Leases for Avalo Therapeutics (AVTX) over the last 7 years, with Q3 2025 value amounting to $402000.0.
- Avalo Therapeutics' Leases fell 6470.59% to $402000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $402000.0, marking a year-over-year decrease of 6470.59%. This contributed to the annual value of $741000.0 for FY2024, which is 4424.38% down from last year.
- Per Avalo Therapeutics' latest filing, its Leases stood at $402000.0 for Q3 2025, which was down 6470.59% from $487000.0 recorded in Q2 2025.
- In the past 5 years, Avalo Therapeutics' Leases ranged from a high of $2.0 million in Q4 2021 and a low of $402000.0 during Q3 2025
- Over the past 5 years, Avalo Therapeutics' median Leases value was $1.3 million (recorded in 2024), while the average stood at $1.2 million.
- Its Leases has fluctuated over the past 5 years, first surged by 15974.21% in 2022, then plummeted by 6470.59% in 2025.
- Over the past 5 years, Avalo Therapeutics' Leases (Quarter) stood at $2.0 million in 2021, then decreased by 12.54% to $1.8 million in 2022, then decreased by 24.06% to $1.3 million in 2023, then crashed by 44.24% to $741000.0 in 2024, then plummeted by 45.75% to $402000.0 in 2025.
- Its last three reported values are $402000.0 in Q3 2025, $487000.0 for Q2 2025, and $615000.0 during Q1 2025.